Hansa Biopharma AB logo

HNSA - Hansa Biopharma AB Share Price

SEK127.9 -2.5  -1.9%

Last Trade - 18/10/19

Sector
Healthcare
Size
Mid Cap
Market Cap £409.4m
Enterprise Value £349.4m
Revenue £270k
Position in Universe 421st / 1491
Bullish
Bearish
Unlock HNSA Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

HNSA Revenue Unlock HNSA Revenue

Net Income

HNSA Net Income Unlock HNSA Revenue

Normalised EPS

HNSA Normalised EPS Unlock HNSA Revenue

PE Ratio Range

HNSA PE Ratio Range Unlock HNSA Revenue

Dividend Yield Range

HNSA Dividend Yield Range Unlock HNSA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
HNSA EPS Forecasts Unlock HNSA Revenue
Profile Summary

Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Public Since October 17, 2007
No. of Shareholders: 12,495
No. of Employees: 60
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 40,026,107
Free Float (0.0%)
Eligible for
ISAs
SIPPs
HNSA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for HNSA
Upcoming Events for HNSA
Thursday 31st October, 2019
Nine Months 2019 Hansa Biopharma AB Earnings Call
Similar to HNSA
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.